Depomed (Lazanda nasal spray) Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Depomed (Lazanda nasal spray) General Information

Description

A nasal spray used for the treatment of cancer pain. The asset consists of a cancer medicine which is designed to deliver a fine mist spray to the nasal membrane to reduce the persistent cancer pain.

Contact Information

Website
www.lazanda.com
Formerly Known As
PecFent
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
Slán Medicinal Holdings
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Depomed (Lazanda nasal spray) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Depomed (Lazanda nasal spray)‘s full profile, request access.

Request a free trial

Depomed (Lazanda nasal spray) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Depomed (Lazanda nasal spray)‘s full profile, request access.

Request a free trial

Depomed (Lazanda nasal spray) FAQs

  • When was Depomed (Lazanda nasal spray) founded?

    Depomed (Lazanda nasal spray) was founded in 2010.

  • Where is Depomed (Lazanda nasal spray) headquartered?

    Depomed (Lazanda nasal spray) is headquartered in .

  • What industry is Depomed (Lazanda nasal spray) in?

    Depomed (Lazanda nasal spray)’s primary industry is Buildings and Property.

  • Is Depomed (Lazanda nasal spray) a private or public company?

    Depomed (Lazanda nasal spray) is a Private company.

  • What is Depomed (Lazanda nasal spray)’s current revenue?

    The current revenue for Depomed (Lazanda nasal spray) is .

  • Who are Depomed (Lazanda nasal spray)’s investors?

    Archimedes Pharma UK and Assertio Holdings have invested in Depomed (Lazanda nasal spray).

  • When was Depomed (Lazanda nasal spray) acquired?

    Depomed (Lazanda nasal spray) was acquired on 07-Nov-2017.

  • Who acquired Depomed (Lazanda nasal spray)?

    Depomed (Lazanda nasal spray) was acquired by Slán Medicinal Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »